Bristol-Myers Squibb Co.’s (BMY) supplemental New Drug Application for the expanded indication of its immunotherapy wonder drug Opdivo in microsatellite instability-high metastatic colorectal cancer is under FDA review – with a decision expected on August 2, 2017.Opdivo, which works by targeting the cellular pathway known as PD-1/PD-L1 (proteins found on the body’s immune cells and some cancer cells), is already approved for a number of indications like melanoma, metastatic, non-small cell lung cancer, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancer, and urothelial carcinoma.The drug brought home sales of $3.77 billion in 2016 compared to $942 million the prior year. BMY closed Friday's (July 28) trading at $55.27, up 1.90%.